Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) will post its quarterly earnings results after the market closes on Tuesday, November 7th. Analysts expect Catalyst Pharmaceuticals to post earnings of ($0.06) per share for the quarter.
Catalyst Pharmaceuticals (NASDAQ:CPRX) last announced its quarterly earnings data on Wednesday, August 9th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.01. On average, analysts expect Catalyst Pharmaceuticals to post $-0.23 EPS for the current fiscal year and $-0.25 EPS for the next fiscal year.
Catalyst Pharmaceuticals, Inc. (CPRX) opened at 2.65 on Tuesday. The company’s market cap is $224.07 million. Catalyst Pharmaceuticals, Inc. has a 52 week low of $0.94 and a 52 week high of $3.20. The firm has a 50-day moving average price of $2.60 and a 200-day moving average price of $2.50.
In other Catalyst Pharmaceuticals news, insider Patrick J. Mcenany purchased 20,000 shares of the firm’s stock in a transaction dated Tuesday, September 5th. The stock was purchased at an average price of $2.58 per share, for a total transaction of $51,600.00. Following the completion of the purchase, the insider now directly owns 4,471,026 shares of the company’s stock, valued at $11,535,247.08. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 8.79% of the stock is owned by insiders.
An institutional investor recently raised its position in Catalyst Pharmaceuticals stock. The Manufacturers Life Insurance Company increased its position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 1,861.3% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 63,114 shares of the biopharmaceutical company’s stock after acquiring an additional 59,896 shares during the period. The Manufacturers Life Insurance Company owned about 0.07% of Catalyst Pharmaceuticals worth $175,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 40.10% of the company’s stock.
Several research analysts have recently weighed in on CPRX shares. Zacks Investment Research cut Catalyst Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, October 11th. Roth Capital set a $5.00 price target on Catalyst Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, August 10th. SunTrust Banks, Inc. restated a “buy” rating and issued a $5.00 price target on shares of Catalyst Pharmaceuticals in a research note on Tuesday, September 5th. Finally, Piper Jaffray Companies set a $6.00 price target on Catalyst Pharmaceuticals and gave the stock a “buy” rating in a research note on Monday, August 7th. One research analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $5.50.
ILLEGAL ACTIVITY NOTICE: “Catalyst Pharmaceuticals, Inc. (CPRX) to Release Earnings on Tuesday” was first posted by Community Financial News and is the sole property of of Community Financial News. If you are reading this story on another site, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be read at https://www.com-unik.info/2017/10/31/catalyst-pharmaceuticals-inc-cprx-to-release-earnings-on-tuesday.html.
Catalyst Pharmaceuticals Company Profile
Catalyst Pharmaceuticals, Inc, formerly Catalyst Pharmaceutical Partners, Inc, is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115.
What are top analysts saying about Catalyst Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Catalyst Pharmaceuticals Inc. and related companies.